Dynamix Pharmaceuticals is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Dynamix Pharmaceuticals. Dynamix is a venture-backed drug discovery and development company focused on cancer and autoimmune disorders. The company’s platform technology, DynamixFit™, is uniquely suitable for discovering novel small-molecule Type II kinase inhibitors that carry the promise of better clinical profiles. Dynamix has created a pipeline of proprietary novel products, and expects to start clinical development in 2011
Address
13 Gad Feinstein Rd.
Company size
11-50 employees